PharmaNutra Group is designing a development plan for its US
subsidiary with the assistance of a leading international strategic
consulting firm
PISA,
Italy, Oct. 30, 2024 /PRNewswire/ -- PharmaNutra
S.p.A. (MTA; Ticker PHN), specializing in mineral-based nutritional
supplements and medical devices for muscles and joints, has signed
an agreement with a prominent strategy consulting firm to define
the development plan for PharmaNutra USA Corp., its American subsidiary based in
Florida, active in the distribution and marketing of the
Group's products in the United
States.
Following a recent market analysis, the renowed American
consulting firm will work over two months to draft a growth plan in
collaboration with PharmaNutra. The development plan starts from
the confirmation of the validity of the choices made so far by the
company founded in 2003 by brothers Andrea
and Roberto Lacorte and aims to enhance business development
in the US market, where PharmaNutra has received in recent years
numerous patents and scientific recognitions from the medical
community.
PharmaNutra USA has already
seen positive feedback in the US market, highlighted by its
participation in the SABM congress in Phoenix last September. This event attracted
global experts discussing Patient Blood Management (PBM), where
interest from various hospital groups in PharmaNutra's products was
evident, particularly the SiderAL® line (SiderAL® Forte and
SiderAL® Folic), nutritional supplements based on Sucrosomial®
Iron, developed on the basis of the patented Sucrosomial®
Technology, which guarantees better absorption, high tolerability,
and gastric resistance.
Additionally, the company has started a direct-to-consumer sales
channel through online platforms like Amazon and Walmart, along
with its e-commerce site (https://pharmanutra-us.com), achieving
initial sales while preparing for a dedicated marketing campaign.
Other products available in the US include the Cetilar® line for
muscle and joint wellness and Apportal®, a complete nutritional
supplement with 19 nutrients to bolster the immune system.
Roberto Lacorte, CEO of
PharmaNutra S.p.A., remarked: "The design of this plan
marks a significant advancement for PharmaNutra USA's business, a project we strongly support.
We are pleased to partner with a leading consulting firm that has
confirmed the growth drivers identified by PharmaNutra S.p.A. and
the substantial potential of the American market for our product
range."
Investor Relations Pharmanutra , 050
7846500 investorrelation@pharmanutra.it
Emanuel Richelmy, Pharmanutra, +39 391 7310645
emrichel@gmail.com
Cristina Tronconi, +39 346 0477901
ctronconi@sprianocommunication.com
Matteo Russo, +39 347 9834881
mrusso@sprianocommunication.com
Logo: https://mma.prnewswire.com/media/1948773/PharmaNutra_SpA_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/pharmanutra-spa-agreement-with-an-international-advisor-in-order-to-define-a-development-plan-for-pharmanutra-usa-302290355.html
SOURCE PharmaNutra S.p.A.